Publicacions en què col·labora amb David León Jiménez (15)

2022

  1. Basal insulin analogues in people with diabetes and chronic kidney disease

    Diabetic Medicine, Vol. 39, Núm. 2

2021

  1. The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives

    Applied Sciences (Switzerland), Vol. 11, Núm. 18

2020

  1. Author Correction: A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function (Scientific Reports, (2019), 9, 1, (5055), 10.1038/s41598-019-41504-7)

    Scientific Reports

  2. In response to the paper ‘High-protein diet: A barrier to the nephroprotective effects of sodium-glucose co-transporter-2 inhibitors?’

    Diabetes, Obesity and Metabolism

  3. Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?

    Kidney International

2019

  1. A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function

    Scientific Reports, Vol. 9, Núm. 1

  2. Could renin-angiotensin-aldosterone system activation explain the amputations associated with canagliflozin? The nitric oxide hypothesis

    Diabetes Research and Clinical Practice, Vol. 148, pp. 10-13

  3. Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors

    Revista Clinica Espanola, Vol. 219, Núm. 4, pp. 208-217

  4. In response to Yaribeygi et al. "Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways"

    Journal of Cellular Physiology

  5. Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months

    Diabetes Research and Clinical Practice, Vol. 158

  6. VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia

    Atherosclerosis, Vol. 285, pp. 17-22

2018

  1. Diabetes tipo 2 bien contralada y microalbuinuria

    Revista Española de Casos Clínicos en Medicina Interna (RECCMI), Vol. 3, Núm. 0, pp. 24-26

  2. Reply to 'Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes' by Yoshimoto et al

    Journal of investigative medicine : the official publication of the American Federation for Clinical Research

  3. The mechanism of action of sodium–glucose co-transporter 2 inhibitors is similar to carbonic anhydrase inhibitors

    European Journal of Heart Failure

  4. Update concept of the dual blocking of the renin-angiotensin-aldosteron system. A new therapeutic option?

    Medicina Clinica, Vol. 150, Núm. 1, pp. 33-38